July 17th 2025
Merck has launched phase 3 trials for MK-8527, a promising once-monthly HIV prevention pill, aiming to enhance PrEP options globally.
Narrowing the Cause of Drug-Drug Interactions in HIV
July 13th 2015Clinically significant drug interactions involving antiretroviral agents have been reported in 30% to 40% of HIV-positive patients in the USA. However, this study finds that just a few therapeutic groups are responsible for most of the interactions detected.
6 Strategies to Get the Most Out of CROI and Other Week-long Meetings
March 3rd 2015CROI offers more than 1100 high-quality presentations and myriad poster sessions. You have so little time. Our CROI blogger offers 6 different ways to maximize learning at any jam-packed meeting, depending on your personal style.